• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday

    11/14/22 2:35:17 AM ET
    $AA
    $ACB
    $AGBA
    $AIRS
    Aluminum
    Industrials
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AA alert in real time by email

    Gainers

    • ShiftPixy, Inc. (NASDAQ:PIXY) shares surged 56.6% to settle at $19.10 on Friday.
    • Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed policy after CPI this week showed October inflation below estimates.
    • Exela Technologies, Inc. (NASDAQ:XELA) gained 50.3% to close at $0.2780. The company is expected to report Q3 results on November 14, 2022.
    • uCloudlink Group Inc. (NASDAQ:UCL) jumped 49.6% to close at $1.90. uCloudlink Group is expected to report Q3 financial results on November 16, 2022.
    • Core Scientific, Inc. (NASDAQ:CORZ) gained 44.3% to settle at $0.1981.
    • Compass, Inc. (NYSE:COMP) jumped 44% to close at $3.50. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates.
    • Kaleyra, Inc. (NYSE:KLR) climbed 38.5% to close at $0.90. Kaleyra extended Oracle partnership to leverage Oracle Cloud.
    • Nutex Health Inc. (NASDAQ:NUTX) gained 37.7% to close at $1.16.
    • MiNK Therapeutics, Inc. (NASDAQ:INKT) jumped 35.8% to close at $3.00.
    • Sight Sciences, Inc. (NASDAQ:SGHT) shares jumped 34.9% to close at $11.28 after the company posted upbeat Q3 sales and raised FY22 revenue outlook.
    • Arrival (NASDAQ:ARVL) gained 34.9% to close at $0.5324. Arrival recently reported a Q3 loss of $310.3 million.
    • Snail, Inc. (NASDAQ:SNAL) shares surged 33.3% to close at $3.00 on Friday after the company announced a $5 million share repurchase program.
    • Orgenesis Inc. (NASDAQ:ORGS) rose 32.9% to settle at $1.90. Orgenesis posted Q3 EPS of $0.05.
    • Doximity, Inc. (NYSE:DOCS) shares gained 32.7% to close at $34.94 after the company reported better-than-expected Q2 results.
    • TransAct Technologies Incorporated (NASDAQ:TACT) climbed 31.9% to close at $5.50 after the company swung to a profit for the third quarter.
    • Tenaya Therapeutics, Inc. (NASDAQ:TNYA) rose 30.9% to close at $2.67. Tenaya Therapeutics posted a Q3 loss of $0.74 per share.
    • XL Fleet Corp. (NYSE:XL) jumped 30.9% to settle at $1.14. XL Fleet recently posted a Q3 loss of $0.15 per share.
    • Canoo Inc. (NASDAQ:GOEV) gained 30.6% to close at $1.58.
    • AGBA Acquisition Limited (NASDAQ:AGBA) jumped 29.6% to close at $7.13 after dipping 50% on Thursday. AGBA Acquisition announced approval of business combination and ability of stockholders to withdraw ordinary shares tendered for redemption.
    • Magenta Therapeutics, Inc. (NASDAQ:MGTA) gained 28.6% to settle at $1.35. Magenta Therapeutics recently posted a Q3 loss of $0.27 per share.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) jumped 28.6% to close at $7.97. Avadel Pharmaceuticals posted a Q3 loss of $0.33 per share.
    • 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) gained 28.6% to close at $12.51. 4D Molecular Therapeutics recently posted a Q3 loss of $0.79 per share.
    • Telos Corporation (NASDAQ:TLS) climbed 28.1% to close at $4.47.
    • Blue Water Vaccines, Inc. (NASDAQ:BWV) gained 28% to settle at $1.37. Blue Water Vaccines posted a Q3 loss of $0.27 per share.
    • Tuniu Corporation (NASDAQ:TOUR) gained 27.9% to close at $0.8840.
    • GlycoMimetics, Inc. (NASDAQ:GLYC) climbed 26.5% to close at $1.24. GlycoMimetics recently posted a Q3 loss of $0.16 per share.
    • Standard BioTools Inc. (NASDAQ:LAB) gained 26.4% to settle at $1.34. Standard BioTools recently posted a Q3 loss of $0.37 per share.
    • Pennsylvania Real Estate Investment Trust (NYSE:PEI) jumped 26.1% to close at $3.58. Pennsylvania Real Estate Investment Trust recently posted a narrower quarterly loss.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) climbed 24.7% to close at $0.4675.
    • Matterport, Inc. (NASDAQ:MTTR) climbed 24.4% to close at $3.77 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates.
    • Zai Lab Limited (NASDAQ:ZLAB) climbed 24.3% to close at $37.76. Zai Lab reported better-than-expected Q3 sales results.
    • Charge Enterprises, Inc. (NASDAQ:CRGE) gained 23.6% to settle at $2.78.
    • Redfin Corporation (NASDAQ:RDFN) rose 21.4% to close at $5.23.
    • GDS Holdings Limited (NASDAQ:GDS) gained 21.3% to close at $13.34 after climbing 20% on Thursday.
    • IGM Biosciences, Inc. (NASDAQ:IGMS) rose 21.3% to close at $25.38. IGM Biosciences Director Kathleen Behrens bought a total of 60,000 shares at an average price of $17.14
    • a.k.a. Brands Holding Corp. (NYSE:AKA) gained 21.2% to close at $1.83 following strong quarterly sales.
    • Sono Group N.V. (NASDAQ:SEV) climbed 21.2% to close at $1.37.
    • Magnite, Inc. (NASDAQ:MGNI) gained 21.2% to settle at $11.60. Magnite recently reported better-than-expected Q3 results.
    • Polestar Automotive Holding UK PLC (NASDAQ:PSNY) rose 20.8% to close at $5.51 after the company reported Q3 earnings results.
    • Agora, Inc. (NASDAQ:API) climbed 20.7% to close at $3.67.
    • XPeng Inc. (NYSE:XPEV) gained 20.6% to close at $8.49. Shares of several Chinese stocks traded higher on reports the country eased Covid measures.
    • Amyris, Inc. (NASDAQ:AMRS) jumped 20.1% to settle at $2.21. Amyris recently reported worse-than-expected Q3 EPS and sales results.
    • Beam Global (NASDAQ:BEEM) rose 19.9% to close at $15.64 after reporting Q3 results.
    • Velo3D, Inc. (NYSE:VLD) jumped 19.5% to settle at $2.94.
    • KE Holdings Inc. (NYSE:BEKE) gained 19.3% to close at $13.53 after gaining 9% on Thursday.
    • LifeMD, Inc. (NASDAQ:LFMD) gained 19.2% to close at $2.48 following strong quarterly earnings.
    • Century Aluminum Company (NASDAQ:CENX) rose 19.1% to close at $9.48. Century Aluminum recently posted a Q3 loss of $0.34 per share.
    • iQIYI, Inc. (NASDAQ:IQ) gained 19.1% to close at $2.75.
    • Carvana Co. (NYSE:CVNA) jumped 18.9% to settle at $11.88.
    • PDF Solutions, Inc. (NASDAQ:PDFS) climbed 18.7% to close at $29.79 following better-than-expected quarterly results.
    • Farfetch Limited (NYSE:FTCH) rose 18.6% to settle at $10.26.
    • Purple Innovation, Inc. (NASDAQ:PRPL) jumped 18.1% to close at $5.28. Purple Innovation recently reported better-than-expected Q3 results and raised its FY22 adjusted EBITDA guidance.
    • 8i Acquisition 2 Corp. (NASDAQ:LAX) gained 17.8% to close at $6.49 after dropping 43% on Thursday.
    • AvePoint, Inc. (NASDAQ:AVPT) surged 17.7% to close at $4.66 following strong quarterly sales.
    • Integral Ad Science Holding Corp. (NASDAQ:IAS) gained 17.5% to close at $8.99.
    • Integral Ad Science named new CFO.
    • Aurora Cannabis Inc. (NASDAQ:ACB) climbed 16.8% to close at $1.53. Aurora Cannabis reported Q1 sales of C$49.3 million.
    • Asana, Inc. (NYSE:ASAN) gained 15.6% to close at $21.70 after jumping 17% on Thursday.
    • Xinyuan Real Estate Co., Ltd. (NYSE:XIN) jumped 15% to settle at $0.4601.
    • Mister Car Wash, Inc. (NYSE:MCW) climbed 14.8% to close at $10.63 following strong quarterly results.
    • NanoString Technologies, Inc. (NASDAQ:NSTG) gained 13.3% to close at $8.29. NanoString Technologies recently reported worse-than-expected Q3 results.
    • Kalera Public Limited Company. (NASDAQ:KAL) gained 11.5% to close at $0.0903 after gaining 10% on Thursday. Kalera recently said it sees Q3 net sales of $1.6 million.
    • Prudential plc (NYSE:PUK) shares climbed 9.1% to settle at $23.86 after gaining 7% on Thursday.
    • Alcoa Corporation (NYSE:AA) gained 8.7% to close at $47.66.
    • Mercurity Fintech Holding Inc. (NYSE:MFH) gained 8.1% to close at $0.5406 after dropping 26% on Thursday.
    • Cosmos Holdings Inc. (NASDAQ:COSM) gained 7% to close at $0.1230 after jumping around 58% on Thursday.

     

    Losers

    • PLx Pharma Inc. (NASDAQ:PLXP) dipped 37.5% to close at $0.3750 on Friday. PLx Pharma posted a Q3 loss of $0.30 per share.
    • Blue Apron Holdings, Inc. (NYSE:APRN) shares dipped 32.2% to close at $1.18 on Friday. Blue Apron filed for offering of up to $30 million of common stock.
    • Science 37 Holdings, Inc. (NASDAQ:SNCE) dipped 32.1% to close at $0.8493 after the company posted downbeat Q3 results and lowered sales guidance.
    • Myomo, Inc. (NYSE:MYO) fell 32.1% to close at $0.91. Myomo posted a Q3 loss of $0.40 per share.
    • AirSculpt Technologies, Inc. (NASDAQ:AIRS) fell 30.7% to close at $3.28 after the company reported worse-than-expected Q3 results.
    • East Stone Acquisition Corporation (NASDAQ:ESSC) dipped 26.8% to settle at $7.30.
    • The Oncology Institute, Inc. (NASDAQ:TOI) dropped 26.2% to close at $2.17. Guggenheim maintained The Oncology Institute with a Buy and lowered the price target from $7 to $6.
    • Brilliant Earth Group, Inc. (NASDAQ:BRLT) shares dipped 25.6% to close at $5.98 after the company issued 2022 sales guidance below estimates.
    • Theseus Pharmaceuticals, Inc. (NASDAQ:THRX) dropped 23.7% to close at $6.38.
    • Ryan Specialty Holdings, Inc. (NYSE:RYAN) fell 23.2% to close at $34.12 after the company reported worse-than-expected Q3 results. Multiple analysts lowered their price targets on the stock following the report.
    • FiscalNote Holdings, Inc. (NYSE:NOTE) dropped 22% to close at $5.14.
    • OncoCyte Corporation (NASDAQ:OCX) dipped 21.7% to settle at $0.47. OncoCyte posted a Q3 loss of $0.08 per share.
    • FlexShopper, Inc. (NASDAQ:FPAY) fell 20.3% to close at $1.22 after the company reported a year-over-year drop in Q3 sales.
    • Algonquin Power & Utilities Corp. (NYSE:AQN) dropped 19.2% to close at $9.30 after the company reported worse-than-expected Q3 EPS.
    • Entera Bio Ltd. (NASDAQ:ENTX) declined 19.2% to close at $0.50.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) declined 19.2% to close at $0.0841 after the company announced a 1-for-50 reverse stock split.
    • GoHealth, Inc. (NASDAQ:GOCO) fell 18.3% to close at $0.4001 after posting downbeat Q3 sales.
    • Rallybio Corporation (NASDAQ:RLYB) dropped 16.6% to close at $5.59. Rallybio announced pricing of $50 million public offering of 5 million shares of common stock at a price of $6 per share.
    • EverCommerce Inc. (NASDAQ:EVCM) dropped 16.3% to close at $6.95 after the company reported worse-than-expected Q3 results. Several analysts lowered their price targets on the stock following the report.
    • Expensify, Inc. (NASDAQ:EXFY) declined 15.8% to close at $10.91 after the company reported worse-than-expected Q3 EPS and sales results.
    • Tattooed Chef, Inc. (NASDAQ:TTCF) fell 14.8% to close at $3.75 after the company lowered its FY22 sales guidance below analyst estimates.
    • Barfresh Food Group, Inc. (NASDAQ:BRFH) declined 14% to close at $1.47. Barfresh reported Q3 sales of $2.4 million.
    • Cue Health Inc. (NASDAQ:HLTH) fell 13.7% to close at $3.54 after the company issued Q4 sales guidance below analyst estimates.
    • Duolingo, Inc. (NASDAQ:DUOL) dipped 13.4% to close at $73.43 after the company issued Q4 revenue guidance with a midpoint below estimates.
    • RedHill Biopharma Ltd. (NASDAQ:RDHL) shares dropped 13.1% to close at $0.5359. RedHill Biopharma recently issued H1/22 highlights and Q3/22 estimates.
    • Aprea Therapeutics, Inc. (NASDAQ:APRE) declined 13% to close at $0.4568. Aprea Therapeutics recently posted a Q3 loss of $0.12 per share.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) dropped 12.7% to settle at $3.64. RBC Capital maintained WAVE Life Sciences with a Sector Perform and lowered the price target from $8 to $5.
    • Kinsale Capital Group, Inc. (NASDAQ:KNSL) fell 10.8% to close at $283.21. Kinsale Capital Group announced pricing of $48.4 million public offering of 155,000 shares of common stock.
    • Flowers Foods, Inc. (NYSE:FLO) dipped 8.5% to settle at $26.90 following Q3 results.
    • Booz Allen Hamilton Holding Corporation (NYSE:BAH) fell 6.8% to close at $103.70.
    • Huntington Ingalls Industries, Inc. (NYSE:HII) fell 6.8% to settle at $227.58. B of A Securities downgraded Huntington Ingalls from Neutral to Underperform.
    Get the next $AA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AA
    $ACB
    $AGBA
    $AIRS

    CompanyDatePrice TargetRatingAnalyst
    Huntington Ingalls Industries Inc.
    $HII
    2/12/2026$400.00Underperform → Neutral
    BofA Securities
    Doximity Inc.
    $DOCS
    2/9/2026$34.00Hold → Buy
    Canaccord Genuity
    Doximity Inc.
    $DOCS
    2/6/2026$40.00Underweight → Neutral
    Analyst
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    KE Holdings Inc
    $BEKE
    2/3/2026$19.00Buy → Neutral
    Goldman
    4D Molecular Therapeutics Inc.
    $FDMT
    1/28/2026$33.00Overweight
    Barclays
    Aurora Cannabis Inc.
    $ACB
    1/27/2026Buy
    Canaccord Genuity
    Compass Inc.
    $COMP
    1/27/2026$14.00Neutral
    Goldman
    More analyst ratings

    $AA
    $ACB
    $AGBA
    $AIRS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.

    SCHEDULE 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/13/26 6:44:35 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PDF Solutions Inc.

    SCHEDULE 13G/A - PDF SOLUTIONS INC (0001120914) (Subject)

    2/13/26 5:48:00 PM ET
    $PDFS
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

    SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

    2/13/26 5:32:38 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ACB
    $AGBA
    $AIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Siokas Grigorios bought $120,000 worth of shares (291,262 units at $0.41), increasing direct ownership by 4% to 8,473,382 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/12/26 2:20:08 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    Director Taitel Haya bought $11,100 worth of Ordinary Shares (7,500 units at $1.48), increasing direct ownership by 8% to 98,479 units (SEC Form 4)

    4 - Entera Bio Ltd. (0001638097) (Issuer)

    2/11/26 8:47:27 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AA
    $ACB
    $AGBA
    $AIRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4DMT Announces New Employment Inducement Grants

    EMERYVILLE, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on February 10, 2026, the compensation committee of the Company's board of directors granted nine new non-executive employees 124,200 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into

    2/13/26 4:05:00 PM ET
    $FDMT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $9.8 Billion in Autonomy Spending Hits the AI-Boosted Defense Supply Chain

    NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – Congress just passed an $839 billion defense spending bill for fiscal 2026, the Pentagon's first full-year appropriation since fiscal 2024, directing $9.8 billion toward autonomous and unmanned systems development across every service branch[1]. That spending lands as the global AI in defense and aerospace market is projected to grow from $4.2 billion in 2026 to $42.8 billion by 2036 at a 26.4% compound annual growth rate, driven by autonomous platforms, AI-enhanced command systems, and sensor fusion architectures that are now embedded in real-world military programs rather than experimental pipelines[2]. The conv

    2/13/26 10:52:29 AM ET
    $CW
    $HII
    $HWM
    Industrial Machinery/Components
    Technology
    Marine Transportation
    Industrials

    Agora, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 2, 2026

    SANTA CLARA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ:API), a pioneer and leader in conversational AI and real-time engagement technology, will release its financial results for the fourth quarter and fiscal year ended December 31, 2025 after the close of U.S. markets on March 2, 2026. Agora, Inc. will host a conference call to discuss the financial results at 5 p.m. Pacific Time / 8 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 4Q 2025 Financial Results The call will be available at https://edge.media-server.com/mmc/p/9jcg52bqInvestors who want to hear the call should log on at least 15 minutes prior to t

    2/13/26 7:00:00 AM ET
    $API
    Computer Software: Prepackaged Software
    Technology

    $AA
    $ACB
    $AGBA
    $AIRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    February 18, 2022 - FDA Alerts the Public to Potentially Contaminated Products from Family Dollar Stores in Six States

    For Immediate Release: February 18, 2022 Today, the U.S. Food and Drug Administration is alerting the public that several categories of FDA-regulated products purchased from Jan. 1, 2021, through the present from Family Dollar stores in Alabama, Arkansas, Louisiana, Mississippi, Missouri and Tennessee may be unsafe for consumers to use. The impacted products originated from the company’s distribution facility in

    2/18/22 8:06:10 PM ET
    $ARVL
    Auto Manufacturing
    Consumer Discretionary

    $AA
    $ACB
    $AGBA
    $AIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Huntington Ingalls upgraded by BofA Securities with a new price target

    BofA Securities upgraded Huntington Ingalls from Underperform to Neutral and set a new price target of $400.00

    2/12/26 7:18:06 AM ET
    $HII
    Marine Transportation
    Industrials

    Doximity upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Doximity from Hold to Buy and set a new price target of $34.00

    2/9/26 6:58:22 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by Analyst with a new price target

    Analyst upgraded Doximity from Underweight to Neutral and set a new price target of $40.00

    2/6/26 8:05:27 AM ET
    $DOCS
    EDP Services
    Technology

    $AA
    $ACB
    $AGBA
    $AIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Sitaram Siddharth claimed ownership of 69,303 shares (SEC Form 3)

    3 - Doximity, Inc. (0001516513) (Issuer)

    2/13/26 9:28:41 PM ET
    $DOCS
    EDP Services
    Technology

    Chief Executive Officer Siokas Grigorios bought $145,000 worth of shares (388,532 units at $0.37), increasing direct ownership by 5% to 8,861,914 units (SEC Form 4)

    4 - Cosmos Health Inc. (0001474167) (Issuer)

    2/13/26 10:05:37 AM ET
    $COSM
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Chief Operating Officer Rodriguez Susan

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    2/12/26 5:36:43 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ACB
    $AGBA
    $AIRS
    Leadership Updates

    Live Leadership Updates

    View All

    Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones

    TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chairman of the Board, effective February 4, 2026. Mr. Germano succeeds Gerald Lieberman, who is stepping down as Chairman. The appointment follows a period of accelerating progress across Entera's pipeline as the Company plans to advance two oral PTH peptide programs into clinical testing within 2026, a Phase 3 registrational study for EB613 in osteoporosis and a first-in-human study for Long-Acting Oral PTH in hypoparathyroidism. "

    2/9/26 8:50:09 AM ET
    $ENTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ryan Specialty Appoints Stephen Stewart CEO of Ryan Specialty Canada Limited

    Ryan Specialty Completes Canadian Amalgamation Ryan Specialty (NYSE:RYAN), a leading international specialty insurance intermediary, is pleased to announce the appointment of Stephen Stewart, President & CEO of Stewart Specialty Risk Underwriting, a Ryan Specialty managing general underwriter, to the additional role Chief Executive Officer of Ryan Specialty Canada Limited, the newly formed Canadian operating and holding entity for Ryan Specialty's underwriting management businesses in Canada. Ryan Specialty Canada Limited is headquartered in Toronto. With the formation of its Canadian holding entity, Ryan Specialty completes the amalgamation of its Canadian operations, including the Can

    2/5/26 8:41:00 AM ET
    $RYAN
    Specialty Insurers
    Finance

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ACB
    $AGBA
    $AIRS
    Financials

    Live finance-specific insights

    View All

    Agora, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 2, 2026

    SANTA CLARA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Agora, Inc. (NASDAQ:API), a pioneer and leader in conversational AI and real-time engagement technology, will release its financial results for the fourth quarter and fiscal year ended December 31, 2025 after the close of U.S. markets on March 2, 2026. Agora, Inc. will host a conference call to discuss the financial results at 5 p.m. Pacific Time / 8 p.m. Eastern Time on the same day. Details for the conference call are as follows: Event title: Agora, Inc. 4Q 2025 Financial Results The call will be available at https://edge.media-server.com/mmc/p/9jcg52bqInvestors who want to hear the call should log on at least 15 minutes prior to t

    2/13/26 7:00:00 AM ET
    $API
    Computer Software: Prepackaged Software
    Technology

    EverCommerce Announces Date of Fourth Quarter 2025 Earnings Call

    DENVER, Feb. 12, 2026 (GLOBE NEWSWIRE) -- EverCommerce Inc. (NASDAQ:EVCM), a leading provider of SaaS solutions for service SMBs, will report its fourth quarter 2025 financial results after the U.S. financial markets close on Thursday, March 12, 2026. Management will host a conference call on Thursday, March 12 at 5:00 p.m. Eastern Time / 3:00 p.m. Mountain Time to discuss the Company's financial results and provide a business update. Please visit the "Investor Relations" page of the Company's website (https://investors.evercommerce.com/) for both telephonic and webcast access to this call; a replay will be archived on the website as well. About EverCommerce EverCommerce (NASDAQ:EVCM) i

    2/12/26 5:00:00 PM ET
    $EVCM
    Computer Software: Prepackaged Software
    Technology

    Kinsale Capital Group, Inc. Reports 2025 Fourth Quarter and Year-End Results

    Kinsale Capital Group, Inc. (NYSE:KNSL) reported net income of $138.6 million, $5.99 per diluted share, for the fourth quarter of 2025 compared to $109.1 million, $4.68 per diluted share, for the fourth quarter of 2024. Net income was $503.6 million, $21.65 per diluted share, for the year ended December 31, 2025 compared to $414.8 million, $17.78 per diluted share, for the year ended December 31, 2024. Net income included after-tax catastrophe losses of $2.3 million in the fourth quarter of 2025 compared to $6.2 million in the fourth quarter of 2024. For the years ended December 31, 2025 and 2024, net income included after-tax catastrophe losses of $24.0 million and $20.2 million, respectiv

    2/12/26 4:10:00 PM ET
    $KNSL
    Property-Casualty Insurers
    Finance

    $AA
    $ACB
    $AGBA
    $AIRS
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

    Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

    6/20/24 6:20:00 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AA
    $ACB
    $AGBA
    $AIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

    SC 13G/A - Oncocyte Corp (0001642380) (Subject)

    12/9/24 5:30:06 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Beam Global

    SC 13G/A - Beam Global (0001398805) (Subject)

    12/6/24 4:12:03 PM ET
    $BEEM
    Semiconductors
    Technology